US EditionAnnovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Annovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported progress on its pivotal Phase 3 trial in early Alzheimer’s disease while posting improved second-quarter financial results and expanding its intellectual property protections. The company now has 76 U.S. clinical sites secured for the trial, with 46 actively enrolling and the remainder expected to begin soon. To date, more than 400 patients have been screened, with 38 receiving buntanetap or …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
